OncoCyte Corp (OCX)

[jonny_red]

My Top Bullish Penny Stocks to Watch on 5.16.2019 $EXBX $OCX $INVU $MARZF $MRGE

https://www.transparenttraders.me/2019/05/my-top-bullish-penny-stocks-to-watch-on_15.html

[pymadams]

My understanding of the progress so far and the plans for the future.
By the end of June this year (2019) they should have concluded all tests so they can proceed to commercialisation.
Reimbursement won't happen until insurance companies see studies showing that it made sense to test with OCX instead of doing a biopsy.

At an OCX presentation earlier in the year they said that they expect some insurance support by the middle of 2020. At the presentation yesterday they said the maximum number of sales reps they would have would be about 40 by 2021. That looks as though they expect to show that the tests save money/ less intrusive by this time and the effort is to get physicians and patients to request the test thru insurance.

It's not clear to me how the progress for the next year will actually work.
If I have a suspected lung cancer, will my Dr say "do you want a potentially dangerous lung biopsy for free or pay 3000 dollars for a test"?
If the tests work will the insurance companies be eager to get a fast adoption or do they make more money when the diagnosis is expensive?

[DMOST]

OncoCyte Corp. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 14, 2019 / OncoCyte Corp. (NYSEMKT: OCX) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 14, 2019 at 4:30 PM Eastern Time.

To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/company/C-A69ABE3B4CA83

To receive updates for this company you can register by emailing [e-mail] or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on the what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network



View source version on accesswire.com:
https://www.accesswire.com/545231/OncoCyte-Corp-to-Host-Earnings-Call



View source version on accesswire.com:
https://www.accesswire.com/545231/OncoCyte-Corp-to-Host-Earnings-Call

GO OCX

"PEACE"

[DMOST]

OncoCyte Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results
https://finance.yahoo.com/news/oncocyte-provides-corporate-reports-fourth-200600373.html

GO OCX

"PEACE"

[DMOST]

OncoCyte Corporation to Present at Cowen and Company 39th Annual Health Care Conference in Boston
GlobeNewswire•March 6, 2019

ALAMEDA, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett, CEO of OncoCyte Corporation, will be presenting at the Cowen and Company 39th Annual Health Care Conference, taking place March 11-13 at the Boston Marriott Copley Place hotel in Boston, Massachusetts.

Cowen and Company 39th Annual Health Care Conference

Date: Wednesday, March 13
Time: 10:00am Eastern Time
Location: Boston Marriott Copley Place
Webcast: http://wsw.com/webcast/cowen52/ocx/

About OncoCyte Corporation

OncoCyte is focused on the development and commercialization of novel, non-invasive blood (“liquid biopsy”) diagnostic tests for the early detection of cancer. Early detection of cancer can improve health outcomes, reduce the cost of care, and improve patients’ quality of life. Liquid biopsy diagnostic tests like those OncoCyte is developing may reduce the need for costlier and riskier diagnostic procedures such as invasive biopsy procedures. OncoCyte’s is focusing its efforts on developing DetermaVu™ as a non-invasive confirmatory diagnostic test for lung cancer. DetermaVu™ is being developed using proprietary sets of genetic and protein molecular markers to detect the presence of lung cancer. OncoCyte also plans to conduct research to identify additional molecular markers, acquire or license markers and related technology, and develop tests for additional types of cancer based on those markers.

Investor Contacts

Bob Yedid
LifeSci Advisors, LLC
[e-mail]
646-597-6989

Media Contact

Andrew Mielach
LifeSci Public Relations
[e-mail]
646-876-5868
https://finance.yahoo.com/news/oncocyte-corporation-present-cowen-company-211500563.html

GO OCX

"PEACE"

[DMOST]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 7, 2019

OncoCyte Corporation

Item 1.01 Entry into a Material Definitive Agreement.

On February 8, 2019, OncoCyte Corporation (the “ Company ”) entered into a purchase agreement (the “ Purchase Agreement ”) with Piper Jaffray & Co., as representative of the underwriters (the “ Underwriters ”), to issue and sell 9,333,334 shares of the Company’s common stock, no par value (“ Common Stock ”), in an underwritten public offering (the “ Offering ”). The offering price to the public is $3.75 per share, and the Underwriters have agreed to purchase the Common Stock from the Company pursuant to the Purchase Agreement at a price of $3.49312 per share. In addition, the Company granted the Underwriters an option (the “ Option ”), for a period of 30 days following February 8, 2019, to purchase up to an additional 1,400,000 shares of Common Stock, which the Underwriters have exercised.

The Company estimates the net proceeds from the Offering, including shares of Common Stock sold pursuant to the Option, are approximately $37.0 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The closing of the Offering occurred on February 12, 2019, upon the satisfaction of customary closing conditions.

The Offering is being made pursuant to the Company’s effective registration statement on Form S-3 (Registration No. 333-220769) (including a prospectus) (the “ Registration Statement ”) filed with, and declared effective by, the Securities Exchange Commission (“ SEC ”) on October 2, 2017 and October 16, 2017, respectively, as supplemented by a preliminary prospectus supplement filed with the SEC on February 7, 2019 and amended on February 8, 2019, and a final prospectus supplement filed with the SEC on February 11, 2019.

The Purchase Agreement contains customary representations, warranties, covenants and agreements by the Company, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. Such representations, warranties and covenants contained in the Purchase Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties.

The foregoing description of the Purchase Agreement is not, and does not purport to be, complete and is qualified in its entirety by reference to the Purchase Agreement, a copy of which is filed as Exhibit 1.1 to this Current Report on Form 8-K and incorporated herein by reference.
https://ih.advfn.com/stock-market/AMEX/oncocyte-corp-OCX/stock-news/79247696/current-report-filing-8-k

GO OCX

"PEACE"

[Shua84]

How long until she goes green?

[CaptStockWolf]

Insider buy today

[DMOST]

From the prospectus...........OCX

DILUTION

If you invest in our common stock in this offering, your interest will be immediately diluted to the extent of the difference between the offering price per share you will pay in this offering and the as adjusted net tangible book value per share of our common stock immediately after this offering.

Our net tangible book value as of September 30, 2018 was approximately $7.5 million, or $0.19 per share. Our net tangible book value is the amount of our total tangible assets less our total liabilities. Net tangible book value per share represents net tangible book value divided by the total number of shares of our common stock outstanding as of September 30, 2018.

After giving effect to the issuance and sale of 9,333,334 shares of common stock in this offering at the public offering price of $3.75 per share, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, the as adjusted net tangible book value as of September 30, 2018 would have been approximately $39.6 million, or $0.79 per share. This represents an immediate increase in net tangible book value of approximately $0.60 per share to our existing shareholders and an immediate dilution in as-adjusted net tangible book value of approximately $2.96 per share to purchasers of our securities in this offering. We determine dilution per share to investors participating in this offering by subtracting as adjusted net tangible book value per share after this offering from the assumed public offering price per share paid by investors participating in this offering.
https://ih.advfn.com/stock-market/AMEX/oncocyte-corp-OCX/stock-news/79227893/prospectus-filed-pursuant-to-rule-424b5-424b5#FORM424B5_HTM_B_007


Looking for it to drift down to near this $2.96 price or below before the next quarter and "Public Share offering", with some chance of positive news, before the announcement, to bolster the price.

GO OCX

"PEACE"

[DMOST]

OCX Share offering done.....

Now what

The company thinks annual DetermaVu revenue can reach $2.1 billion as a test for patients with large nodules that show up on CT scans, and $4.7 billion if expanded to include medium-size growths as well. The company has another validation study to complete later this year and expects to launch DetermaVu in the second half if all goes according to plan. In recent years, the FDA has threatened to crack down on new lab tests that heavily influence treatment decisions, and the agency could decide DetermaVu needs to jump through a lot more regulatory hoops than expected.

Full-scale clinical trials to please the FDA would cause expenses to explode for OncoCyte, but investors need to brace for a secondary share offering even if all goes according to plan. OncoCyte finished September with just $11.8 million in cash after losing $11.2 million during the first nine months of 2018.
https://finance.yahoo.com/news/apos-why-oncocyte-giving-back-171500642.html

GO OCX

"PEACE"

[sqrl]

[DMOST]

A share offering....It's what commonly happens. At what price you ask?

OncoCyte Announces Proposed Public Offering of Common Stock
https://finance.yahoo.com/news/oncocyte-announces-proposed-public-offering-210500269.html

Probably lower than the $4.52 price noted at filing.....As after hours price action print the bidding price higher than the ask....GO FIGURE!

GO OCX

"PEACE"

Someone(s) seem determined to sell it down.....GO FIGURE!

[Shua84]

Yea, I guess by next year this thing should be poppin!! Screw cancer and let me make some money!!!

[DMOST]

There have been price expectations and analytical upgrades to as much as $8 a share?

With news of any substance share price could flow past recent resistance near $7?

WE WILL SEE!

GO OCX

"PEACE"

[Shua84]

Me too! How big of a bounce you thinking?

[DMOST]

Agreed. Should and would be a premier buyout candidate? they ruled out partnering with anyone at this time?

HOLDING, WAITING FOR THE BIG BOUNCE!

GO OCX

"PEACE"

[Shua84]

Why is there no updated news on this company? Should be skyrocketing with more news, Let’s go OCX!

[DMOST]

Here's Why OncoCyte Is Giving Back Some Gains Today
[Motley Fool]

What happened

Shares of OncoCyte (NYSEMKT: OCX), a company developing noninvasive cancer tests, are giving back some of yesterday's gains. Successful validation of OncoCyte's liquid biopsy sent shares soaring 208% yesterday. The stock has tumbled 15.6% during early-morning trading and was down by 10.5% as of 11:45 a.m. Wednesday.

So what

OncoCyte is a modestly funded operation with explosive sales potential. Its DetermaVu liquid biopsy test for lung cancer recently demonstrated results that suggest it might work. The company used 250 blood samples from patients who had also undergone biopsies, and DetermaVu correctly identified malignancies 90% of the time.

OncoCyte's test also correctly identified benign growths 75% of the time. At the moment, the only way to know if tiny spots that show up on a CT scan are malignant is to reach inside and pull out a chunk of the lung. Around one in five lung cancer biopsies result in potentially serious complications, which makes screening for lung cancer a tough decision for patients and their physicians. DetermaVu isn't meant to replace the use of biopsies, but it could be extremely useful for determining whether performing one is worth the risk.

Now what

The company thinks annual DetermaVu revenue can reach $2.1 billion as a test for patients with large nodules that show up on CT scans, and $4.7 billion if expanded to include medium-size growths as well. The company has another validation study to complete later this year and expects to launch DetermaVu in the second half if all goes according to plan. In recent years, the FDA has threatened to crack down on new lab tests that heavily influence treatment decisions, and the agency could decide DetermaVu needs to jump through a lot more regulatory hoops than expected.

Full-scale clinical trials to please the FDA would cause expenses to explode for OncoCyte, but investors need to brace for a secondary share offering even if all goes according to plan. OncoCyte finished September with just $11.8 million in cash after losing $11.2 million during the first nine months of 2018.
https://finance.yahoo.com/news/apos-why-oncocyte-giving-back-171500642.html

Well this and the fact that some are rightfully exiting with profits.

Volume on yesterday over 44m vs today a little over 6m? A huge upside still exist.

WE WILL SEE...........

GO OCX

"PEACE"

[DMOST]

BioTime Inc. Affiliate Company OncoCyte Corporation Reports Successful Results With DetermaVu™ Diagnostic Test for Lung Cancer
https://finance.yahoo.com/news/biotime-inc-affiliate-company-oncocyte-130000269.html

Looks worth getting a piece of this one also...

GO OCX

"PEACE"

[DMOST]

Today's Research Reports on Trending Tickers: Amgen and OncoCyte
https://finance.yahoo.com/news/todays-research-reports-trending-tickers-130000490.html

GO OCX

"PEACE"

[DMOST]

Has OncoCyte Changed How We Will Diagnose Cancer in the Near Future?

ACCESSWIRE•January 30, 2019

NEW YORK, NY / ACCESSWIRE / January 30, 2019 / Traders News Source, a leading independent equity researchand corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on OncoCyte Corporation (NYSE American: OCX) focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer.

On Tuesday, January 29, 2019, the company shares soared significantly on news that a study of their cancer diagnosis test indicated positive results
https://finance.yahoo.com/news/oncocyte-changed-diagnose-cancer-near-133000281.html

GO OCX

"PEACE'

[DMOST]

OCX.....Okay i'm in for a sip, taking some advantage of this post rocket-up dip.

Could go lower, as Clay Trader and the gang floor her. But if what they've got is further confirmed as fact, then the share price will again react.

More speculative gains to be made here, both short and long term.

WE WILL SEE........

GO OCX

"PEACE"

[Shua84]

Why is nobody talking about this stock?

[ClayTrader]

* * $OCX Video Chart 01-29-2019 * *

Link to Video - click here to watch the technical chart video

[$$$MADE]

,,,,,,,5.70+3.88 (+213.19%) CANCER DETECTION FOR UNDER $6BUCKS

[ALERTS100%to10000%GAIN]

OCX out at 5.89,see yea next time

[ALERTS100%to10000%GAIN]

OCX~221%5 up and going

[ALERTS100%to10000%GAIN]

OCX~~5.85 wowwwwwwwwwwwwwwwwww

[ALERTS100%to10000%GAIN]

OCX~~WEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE,200%%% +++ going

[ClayTrader]

* * $OCX Video Chart 07-10-18 * *

Link to Video - click here to watch the technical chart video

[swampboots]

They have many warrants flying around, so its a lotto.

[Churak]

gravity has set in compared to AH yesterday

[swampboots]

OT: ISR in my opinion yesterday's play as "news"not that big except on technical wig try ons.

[capital gain]

that is indeed a massive gap, 164000 shares sold and it went to $4.95.

Cannot wait to see what tomorrow brings.

[Churak]

and then a GINORMOUS gap up in AH

[Churak]

well, this came alive after I sold half...bastages...

[halbroke1]

OCX $$$$ HUGE BUYOUT OFFER COULD BE COMING...NO SHARES LEFT $$$$ WOW!!!..

[halbroke1]

OCX $$$$$$$ MASSIVE MOVE !!!!! GET READY !!

[capital gain]

76 percent of the shares are owned by Biotime, and they are not for sale. With an OS of 32 mil shares, that leaves only 7.7 million shares available to trade, as the recent 8 million shares from the placement are restricted for sale. A whiff of volume and this thing will fly.

Huge drop from over 6 Dollar 3 months ago, no doubt the people buying into this placement of shares were responsible for some of that, to push the share price to just under the placement price of $1.26, hence why it rebounded so violently the day after the placement was confirmed.
Still lots of room for this thing to move 50 Day MA is a $3.03 the next one the 200 day MA is all the way up at $4.76.

I reckon it will go through the 50 Day MA very easily on the way to the 200 Day MA.

[capital gain]

And it certainly did! up 7% on the day in a blood red market, that is very good going. No doubt many eyes will look at this one tonight, as todays green stocks will stand out like a sore thump.

Once they realised how oversold this thing is and how far it can still go up, there will be a lot of buying decisions made I am sure.

Tomorrow could be huge if DOW makes a rebound.

[halbroke1]

POWER-HOUR HERE...OCX...IS GOING TO ROCK...

[capital gain]

OCX one of only a handful of stocks in the green today, very bullish IMO, if DOW turns tomorrow expect to see increased volume here and an exploding share price.

Very encouraging trading today, holding out for $7

[ALERTS100%to10000%GAIN]

agreed,bids moving up,will break here

[halbroke1]

OCX $$$ READY TO BLOW UP !!!! READY FOR $10.00++

[ALERTS100%to10000%GAIN]

OCX~~will run hard to $7.00

[capital gain]

It could indeed take off, with the money just raised they will have enough to get their lung cancer test kit in the market, this could become quite a revenue earner.

They have no debt and are not in risk of any bankruptcy, with only 40 mil OS including the ones from recent placement and an amazing product line, they could indeed become quite a successful company,

[halbroke1]

OCX $$$$ COULD BE HUGE NEXT WEEK...$8.00- $10.00 VERY POSSIBLE.

[ALERTS100%to10000%GAIN]

OCX~~HUGE HERE Purpose of Transaction.


The Reporting Persons have acquired their Shares for investment and are filing this Schedule 13D/A to report a change in their beneficial ownership percentage of the Shares, as indicated in Item 5 below.



In connection with the Issuer’s private placement of Shares, on March 28, 2018, the Issuer and Broadwood Partners entered into a Securities Purchase Agreement pursuant to which Broadwood Partners acquired 3,968,254 Shares at a purchase price of $1.26 per share. The foregoing description is not, and does not purport to be, complete and are qualified in their entirety by reference to the full text of the Form of Securities Purchase Agreement, which has been filed as Exhibit B hereto and is incorporated herein by reference.



Except as otherwise set forth herein, the Reporting Persons have no plans or proposals as of the date of this filing which, other than as expressly set forth below, would relate to or would result in: (a) any extraordinary corporate transaction involving the Issuer; (b) any change in the present board of directors of the Issuer (the “Board of Directors”) or management of the Issuer; (c) any material change in the present capitalization or dividend policy of the Issuer; (d) any material change in the operating policies or corporate structure of the Issuer; (e) any change in the Issuer's charter or by-laws; (f) the Shares of the Issuer ceasing to be authorized to be quoted in the NASDAQ inter-dealer quotation system; or (g) causing the Issuer to become eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934.



The Reporting Persons, however, reserve the right at a later date to effect one or more of such changes or transactions in the number of Shares they may be deemed to beneficially own.





The Reporting Persons have been, and may continue to be, in contact with members of the Issuer’s management, the Board of Directors, other significant shareholders and others regarding alternatives that the Issuer could employ to maximize shareholder value.



The Reporting Persons further reserve the right to act in concert with any other shareholders of the Issuer, or other persons, for a common purpose should it determine to do so, and/or to recommend courses of action to shareholders, the Board of Directors and/or the management of the Issuer.







Item 5. Interest in Securities of the Issuer.

(a) – (d) As of the date hereof, Broadwood Partners may be deemed to be the beneficial owner of 8,620,895 Shares, constituting 21.3% of the Shares, based upon 40,461,027 Shares outstanding as of the date hereof as adjusted for warrants beneficially owned by Broadwood Partners. Broadwood Partners has the sole power to vote or direct the vote of 0 Shares and the shared power to vote or direct the vote of 8,620,895 Shares. Broadwood Partners has sole power to dispose or direct the disposition of 0 Shares the shared power to dispose or direct the disposition 8,620,895 Shares.

As of the date hereof, Broadwood Capital may be deemed to be the beneficial owner of 8,620,895 Shares, constituting 21.3% of the Shares, based upon 40,461,027 Shares outstanding as of the date hereof as adjusted for warrants beneficially owned by Broadwood Capital. Broadwood Capital has the sole power to vote or direct the vote of 0 Shares and the shared power to vote or direct the vote of 8,620,895 Shares. Broadwood Capital has sole power to dispose or direct the disposition of 0 Shares the shared power to dispose or direct the disposition 8,620,895 Shares.


As of the date hereof, Mr. Bradsher may be deemed to be the beneficial owner of 8,624,040 Shares, constituting 21.3% of the Shares, based upon 40,461,027 Shares outstanding as of the date hereof as adjusted for warrants beneficially owned by Mr. Bradsher. Mr. Bradsher has the sole power to vote or direct the vote of 3,145 Shares and the shared power to vote or direct the vote of 8,620,895 Shares. Mr. Bradsher has sole power to dispose or direct the disposition of 3,145 Shares the shared power to dispose or direct the disposition 8,620,895 Shares.



Other than the Shares acquired by the Reporting Persons pursuant to the Securities Purchase Agreement as described in Item 4 above, there have been no transactions in the Shares by the Reporting Persons during the past sixty days.




(e) N/A

[ALERTS100%to10000%GAIN]

OCX~~Source and Amount of Funds or Other Consideration.


The funds for the purchase of the 8,620,895 Shares beneficially owned by Broadwood Partners came from its working capital. No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working capital purposes in the ordinary course of business.



The funds for the purchase of the 8,620,895 Shares beneficially owned by Broadwood Capital came from the working capital of Broadwood Partners, which is the direct owner of the Shares. No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working capital purposes in the ordinary course of business.



The funds for the purchase of the 8,624,040 Shares beneficially owned by Mr. Bradsher came from his personal funds and the working capital of Broadwood Partners. No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working capital purposes in the ordinary course of business.

[ALERTS100%to10000%GAIN]

OCX is gonna run hard